This is the authors' abstract. We don't add key points for this paper.
A better alignment of preclinical and clinical neurobiological measures could help improve neuropsychiatric disease therapeutic development. This unit describes a compendium of hypothesis-driven neuroanatomical phenotyping strategies to be employed in genetic mouse models. Using neuropsychiatric disease-based alterations as a guide, these are histological and immunohistochemical methodologies also applied to human tissue. They include quantification assays of neurochemical-, newly born neuron- and glial-cell markers, synaptic proteins, regional volumetrics, dendritic complexity and spine number as well as an index of excitation/inhibition balance. The techniques can be implemented in isolation or to complement concordant behavioral and electrophysiological analyses. Each outcome will provide functional detail necessary to decipher underlying neural circuit abnormalities associated with a brain-related phenotype in mice. Experimental design, timing, anticipated results and potential pitfalls are discussed.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Garrett et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: